Valuation: Avacta Group Plc

Market Cap 287M 376M 342M 316M 539M 34.82B 567M 3.84B 1.52B 19.01B 1.41B 1.38B 59.65B P/E 2026 *
-8.55x
P/E 2027 * -14.2x
Enterprise Value 281M 368M 335M 309M 528M 34.1B 555M 3.76B 1.48B 18.61B 1.38B 1.35B 58.42B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.82%
Yield 2026 *
-
Yield 2027 * -
1 day-2.48%
Current month-2.48%
1 month-10.20%
3 months-13.24%
6 months-24.46%
Current year+1.72%
1 week 56
Extreme 56
63
1 month 52
Extreme 52
67
Current year 48
Extreme 48
92
1 year 48
Extreme 48
92
3 years 26
Extreme 26
143.5
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Director/Board Member 59 28/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/24 Sell

Chief Financial Officer

500,000 0.1393%
2/9/24 Free

Chief Executive Officer

3,600,000 1.0027%
2/9/24 Exercice

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
-2.48%0.00%-23.38%-55.30% 376M
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.48%-1.09%+27.42%+156.95% 40B
Weighted average by Cap. -1.48%-1.85%+31.77%+154.94%

Financials

2026 *2027 *
Net sales - -
Net income -35.42M -46.36M -42.23M -38.96M -66.49M -4.29B -69.94M -473M -187M -2.34B -174M -170M -7.36B -14.1M -18.45M -16.81M -15.51M -26.46M -1.71B -27.83M -188M -74.39M -933M -69.09M -67.77M -2.93B
Net Debt -5.94M -7.77M -7.08M -6.53M -11.14M -720M -11.72M -79.32M -31.32M -393M -29.09M -28.53M -1.23B 5.65M 7.4M 6.74M 6.22M 10.61M 685M 11.16M 75.55M 29.83M 374M 27.71M 27.18M 1.17B
Projected Income Statement - Annual - Avacta Group Plc
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
20/11/26 GBX 59.00 -2.48% 2,050,019
19/11/26 GBX 60.50 +6.51% 2,050,040
18/11/26 GBX 56.80 -0.35% 1,434,282
17/11/26 GBX 57.00 -0.18% 1,169,757
16/11/26 GBX 57.10 -3.22% 797,067
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Avacta Group Plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.5900GBP
Average target price
0.9050GBP
Spread / Average Target
+53.39%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Avacta Group Plc
  1. Stock Market
  2. Stocks
  3. AVCT Stock
BLACK FRIDAY -Get 40% off all subscriptions
BLACK FRIDAY40% off all subscriptions
Get the offer